IIT RESEARCH INSTITUTE
Reduce your risk when donating: see where the money actually goes.
Reduce your risk when donating: see where the money actually goes.
Cite this
Plain text IIT RESEARCH INSTITUTE. furp.org, nonprofit organization profile, tax years 2019–2024. https://furp.org/org/iit-research-institute-362169122. Retrieved 2026-11-16.
APA furp.org. (n.d.). IIT RESEARCH INSTITUTE [Nonprofit organization profile; tax years 2019–2024]. Retrieved November 16, 2026, from https://furp.org/org/iit-research-institute-362169122
MLA “IIT RESEARCH INSTITUTE.” furp.org, tax years 2019–2024, https://furp.org/org/iit-research-institute-362169122. Accessed 16 Nov. 2026.
Retrieved 2026-11-16; covers tax years 2019–2024. Data: furp.org (index © the FURP Alliance; the records are public domain).
About (Wikipedia)
IIT Research Institute · American think tank
IIT Research Institute (IITRI), also known historically and interchangeably as IIT Research Center, is a high-technology scientific research organization and applied research laboratory located in Chicago, Illinois.
- Founded
- 1936
- Headquarters
- Chicago
- Type
- business
- Website
- http://www.iitri.org
From Wikipedia, CC BY-SA 4.0 (authors and history); facts from Wikidata (CC0). Matched by the same website address and the same name. Report a wrong match · About this data
2024 · Form 990 · revenue $17.5M ($18.0M in 2025 dollars) · expenses $23.0M · assets $36.3M
- EIN
- 36-2169122
- Address
- 10 WEST 35TH STREET, CHICAGO, IL 60616-3717
- Website
- www.iitri.org
- NTEE code
- U20 General Science (Science and Technology) published (IRS Business Master File, as U200)
- FURP topic
- science: research education (from its 990 text; the topic index)
- Exempt type
- 501(c)(3): charitable, religious, educational, scientific or literary (corporation)
- Ruling date
- March 1941 (when the IRS recognized its exemption)
- IRS status
- Exempt (unconditional) (IRS Business Master File) IRS data ↗
- Tax-deductible donations
- Yes: listed in IRS Publication 78 (public charity) Pub 78 ↗
- Foundation status
- Public charity, 509(a)(2)
- Cross-check
- ProPublica Nonprofit Explorer
Mission
Perform basic research and preclinical efficacy assessments of new molecular entities being developed for the prevention and treatment of cancer and infectious disease. Discover new pathways and targets for the design and development of new small molecule therapeutics and biotherapeutic agents.
Each tax year counts once: when a return was amended, only the latest return for that period is used below (superseded returns stay listed, greyed, under Finances).
People paid by the organization
21 people paid across every filing: current people first, then by total pay from this organization. Organizations counts every nonprofit each person appears on.
| Name | Latest title | Years | Latest year pay | Total pay from here | Organizations |
|---|---|---|---|---|---|
| David McCormick | President & Director | 2019-2024 | $581,526 | $2,642,741 | 1 |
| Todd Bucciarelli | AVP & Business Development Manager | 2019-2024 | $311,525 | $1,583,594 | 1 |
| Robert Baker | AVP & Mgr Microbiology & Molecular Biology | 2019-2024 | $265,932 | $1,403,592 | 1 |
| Thomas Horn | Deputy Division Manager Toxicology | 2019-2024 | $245,251 | $1,172,089 | 1 |
| Kelly Garcia | Attending Veterinarian | 2021-2024 | $254,458 | $982,703 | 1 |
| Nicole Kozub | Laboratory Biologist IV/Supervisor | 2021-2024 | $191,702 | $810,878 | 1 |
| David Kaplan | Assistant Vice President & Director of Contracts | 2022-2024 | $232,058 | $664,315 | 1 |
| Landon Westfall | Deputy Division Manager | 2022-2024 | $201,016 | $589,391 | 1 |
| Aleemuddin Muhammad | Manager of IT & Cybersecurity | 2022-2024 | $198,611 | $587,574 | 1 |
| Sudhakar Parthasarathy | Head, Analytical Chemistry | 2023-2024 | $224,496 | $430,225 | 1 |
| Mary Smeaton | Manager, Human Resources | 2023-2024 | $176,157 | $349,542 | 1 |
| Myron H Powelson IV | Director, Finance & Accounting | 2024 | $218,072 | $218,072 | 1 |
| William Johnson (former) | AVP & Manager Toxicology | 2019-2022 | $268,461 | $880,278 | 1 |
| Miguel Muzzio (former) | VP & Deputy Director, Mgr Analytical Chemistry | 2019-2021 | $239,771 | $627,566 | 1 |
| Glenn Miller (former) | AVP & QA Manager | 2019-2021 | $178,574 | $492,459 | 1 |
| Sridhar Jaligama (former) | Deputy Division Manager/Study Director | 2021-2022 | $226,218 | $410,018 | 1 |
| Ethan H Landesman (former) | Director of Finance & Accounting | 2020-2021 | $216,332 | $381,474 | 1 |
| Theodore Francis (former) | Manager IT & Cyber Security | 2019-2020 | $157,661 | $313,746 | 1 |
| Michael McGibbon (former) | VP & Director for Administration | 2019-2020 | $112,434 | $271,019 | 1 |
| Narayanan Rajendran (former) | VP & Mgr Inhalation Toxicology | 2019 | $170,430 | $170,430 | 1 |
| Tate W Brummitt (former) | Director of Contracts & Procurement | 2020 | $146,919 | $146,919 | 1 |
Officers and directors, no compensation reported
11 people listed on the returns with $0 (or no amount) in every compensation column: current people first. Hours are as filed on the latest return each person appears on.
| Name | Latest title | Years | Hrs/wk (latest) | Compensation | Organizations |
|---|---|---|---|---|---|
| Walter Hazlitt | Secretary & Interim General Counsel | 2020-2024 | 0 | $0 reported | 2 |
| Rajagopal R Echambadi | Chairman & CEO | 2020-2024 | 0 | $0 reported | 1 |
| Jeremy Fine | Treasurer, VP Finance & CFO | 2023-2024 | 0 | $0 reported | 2 |
| Elizabeth Hudson | Provost, SVP Academic Affairs & Member | 2023-2024 | 0 | $0 reported | 1 |
| Angela Manning-Hardiman (former) | Treasurer, VP Finance & CFO | 2020-2022 | 0 | $0 reported | 1 |
| Kenneth T Christensen (former) | Provost, SVP Academic Affairs & Member | 2020-2022 | 0 | $0 reported | 1 |
| Alan Cramb (former) | Chairman, CEO & President | 2019 | 1 | $0 reported | 7 |
| Peter Kilpatrick (former) | Member, Board of Governors | 2019 | 1 | $0 reported | 2 |
| Anthony D'Amato (former) | Secretary, VP & General Counsel | 2019 | 1 | $0 reported | 3 |
| Michael D Horan (former) | Treasurer, VP & CFO | 2019 | 1 | $0 reported | 1 |
| Mary Ellen Borchers (former) | Interim VP of Finance | 2019 | 1 | $0 reported | 1 |
People by year
2024 · 16 people listed · 12 paid, $3.1M · 128 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| David McCormick | President & Director | 40 | $532,005 | $0 | $49,521 | $581,526 | 1 |
| Todd Bucciarelli | AVP & Business Development Manager | 40 | $262,728 | $0 | $48,797 | $311,525 | 1 |
| Robert Baker | AVP & Mgr Microbiology & Molecular Biology | 40 | $225,381 | $0 | $40,551 | $265,932 | 1 |
| Kelly Garcia | Attending Veterinarian | 40 | $211,693 | $0 | $42,765 | $254,458 | 1 |
| Thomas Horn | Deputy Division Manager Toxicology | 40 | $202,154 | $0 | $43,097 | $245,251 | 1 |
| David Kaplan | Assistant Vice President & Director of Contracts | 40 | $206,800 | $0 | $25,258 | $232,058 | 1 |
| Sudhakar Parthasarathy | Head, Analytical Chemistry | 40 | $198,793 | $0 | $25,703 | $224,496 | 1 |
| Myron H Powelson IV | Director, Finance & Accounting | 40 | $174,668 | $0 | $43,404 | $218,072 | 1 |
| Landon Westfall | Deputy Division Manager | 40 | $174,720 | $0 | $26,296 | $201,016 | 1 |
| Aleemuddin Muhammad | Manager of IT & Cybersecurity | 40 | $156,618 | $0 | $41,993 | $198,611 | 1 |
| Nicole Kozub | Laboratory Biologist IV/Supervisor | 40 | $164,176 | $0 | $27,526 | $191,702 | 1 |
| Mary Smeaton | Manager, Human Resources | 40 | $145,725 | $0 | $30,432 | $176,157 | 1 |
| Rajagopal R Echambadi | Chairman & CEO | 0 | $0 | $0 | $0 | $0 | 1 |
| Walter Hazlitt | Secretary & Interim General Counsel | 0 | $0 | $0 | $0 | $0 | 2 |
| Jeremy Fine | Treasurer, VP Finance & CFO | 0 | $0 | $0 | $0 | $0 | 2 |
| Elizabeth Hudson | Provost, SVP Academic Affairs & Member | 0 | $0 | $0 | $0 | $0 | 1 |
2023 · 15 people listed · 11 paid, $2.7M · 127 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| David McCormick | President & Director | 40 | $377,150 | $0 | $74,696 | $451,846 | 1 |
| Todd Bucciarelli | AVP & Business Development Manager | 40 | $280,549 | $0 | $55,430 | $335,979 | 1 |
| Robert Baker | AVP & Mgr Microbiology & Molecular Biology | 40 | $213,339 | $0 | $40,711 | $254,050 | 1 |
| Kelly Garcia | Attending Veterinarian | 40 | $206,845 | $0 | $44,338 | $251,183 | 1 |
| Nicole Kozub | Laboratory Biologist IV/Supervisor | 40 | $200,403 | $0 | $30,103 | $230,506 | 1 |
| Thomas Horn | Deputy Division Manager Toxicology | 40 | $178,970 | $0 | $43,127 | $222,097 | 1 |
| David Kaplan | Assistant Vice President & Director of Contracts | 40 | $189,311 | $0 | $25,566 | $214,877 | 1 |
| Sudhakar Parthasarathy | Head, Analytical Chemistry | 40 | $190,529 | $0 | $15,200 | $205,729 | 1 |
| Aleemuddin Muhammad | Manager of IT & Cybersecurity | 40 | $155,491 | $0 | $45,701 | $201,192 | 1 |
| Landon Westfall | Deputy Division Manager | 40 | $167,079 | $0 | $26,087 | $193,166 | 1 |
| Mary Smeaton | Manager, Human Resources | 40 | $138,201 | $0 | $35,184 | $173,385 | 1 |
| Rajagopal R Echambadi | Chairman & CEO | 0 | $0 | $0 | $0 | $0 | 1 |
| Walter Hazlitt | Secretary & Interim General Counsel | 0 | $0 | $0 | $0 | $0 | 2 |
| Jeremy Fine | Treasurer, VP Finance & CFO | 0 | $0 | $0 | $0 | $0 | 2 |
| Elizabeth Hudson | Provost, SVP Academic Affairs & Member | 0 | $0 | $0 | $0 | $0 | 1 |
2022 · 15 people listed · 11 paid, $2.8M · 157 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| David McCormick | President & Director | 40 | $422,808 | $0 | $42,266 | $465,074 | 1 |
| Robert Baker | AVP & Mgr Microbiology & Molecular Biology | 40 | $233,707 | $0 | $38,030 | $271,737 | 1 |
| William Johnson | AVP & Manager Toxicology | 40 | $230,851 | $0 | $37,610 | $268,461 | 1 |
| Todd Bucciarelli | AVP & Business Development Manager | 40 | $218,622 | $0 | $45,485 | $264,107 | 1 |
| Kelly Garcia | Attending Veterinarian | 40 | $208,494 | $0 | $39,812 | $248,306 | 1 |
| Sridhar Jaligama | Deputy Division Manager/Study Director | 40 | $174,716 | $0 | $51,502 | $226,218 | 1 |
| David Kaplan | Assistant Vice President & Director of Contracts | 40 | $199,903 | $0 | $17,477 | $217,380 | 1 |
| Thomas Horn | Deputy Division Manager Toxicology | 40 | $175,935 | $0 | $38,959 | $214,894 | 1 |
| Nicole Kozub | Laboratory Biologist IV/Supervisor | 40 | $173,579 | $0 | $24,918 | $198,497 | 1 |
| Landon Westfall | Deputy Division Manager | 40 | $178,875 | $0 | $16,334 | $195,209 | 1 |
| Aleemuddin Muhammad | Manager of IT & Cybersecurity | 40 | $152,312 | $0 | $35,459 | $187,771 | 1 |
| Rajagopal R Echambadi | Chairman & CEO | 0 | $0 | $0 | $0 | $0 | 1 |
| Walter Hazlitt | Secretary & Interim General Counsel | 0 | $0 | $0 | $0 | $0 | 2 |
| Angela Manning-Hardiman | Treasurer, VP Finance & CFO | 0 | $0 | $0 | $0 | $0 | 1 |
| Kenneth T Christensen | Provost, SVP Academic Affairs & Member | 0 | $0 | $0 | $0 | $0 | 1 |
2021 · 15 people listed · 11 paid, $2.7M · 152 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| David McCormick | President & Director | 40 | $406,233 | $0 | $42,385 | $448,618 | 1 |
| Todd Bucciarelli | AVP & Business Development Manager | 40 | $269,090 | $0 | $47,188 | $316,278 | 1 |
| Robert Baker | AVP & Mgr Microbiology & Molecular Biology | 40 | $213,349 | $0 | $35,475 | $248,824 | 1 |
| William Johnson | AVP & Manager Toxicology | 40 | $205,448 | $0 | $36,792 | $242,240 | 1 |
| Miguel Muzzio | VP & Deputy Director, Mgr Analytical Chemistry | 40 | $215,356 | $0 | $24,415 | $239,771 | 1 |
| Kelly Garcia | Attending Veterinarian | 40 | $195,389 | $0 | $33,367 | $228,756 | 1 |
| Ethan H Landesman | Director of Finance & Accounting | 40 | $195,090 | $0 | $21,242 | $216,332 | 1 |
| Thomas Horn | Deputy Division Manager Toxicology | 40 | $160,077 | $0 | $37,041 | $197,118 | 1 |
| Nicole Kozub | Laboratory Biologist IV/Supervisor | 40 | $166,734 | $0 | $23,439 | $190,173 | 1 |
| Sridhar Jaligama | Deputy Division Manager/Study Director | 40 | $148,751 | $0 | $35,049 | $183,800 | 1 |
| Glenn Miller | AVP & QA Manager | 40 | $169,139 | $0 | $9,435 | $178,574 | 1 |
| Rajagopal R Echambadi | Chairman & CEO | 1 | $0 | $0 | $0 | $0 | 1 |
| Walter Hazlitt | Secretary & Interim General Counsel | 1 | $0 | $0 | $0 | $0 | 2 |
| Angela Manning-Hardiman | Treasurer, VP Finance & CFO | 1 | $0 | $0 | $0 | $0 | 1 |
| Kenneth T Christensen | Provost, SVP Academic Affairs & Member | 1 | $0 | $0 | $0 | $0 | 1 |
2020 · 15 people listed · 11 paid, $2.0M · 150 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| David McCormick | President & Director | 40 | $341,800 | $0 | $20,137 | $361,937 | 1 |
| Miguel Muzzio | VP & Deputy Director, Mgr Analytical Chemistry | 40 | $191,623 | $0 | $11,317 | $202,940 | 1 |
| Todd Bucciarelli | AVP & Business Development Manager | 40 | $182,103 | $0 | $10,497 | $192,600 | 1 |
| William Johnson | AVP & Manager Toxicology | 40 | $180,828 | $0 | $10,705 | $191,533 | 1 |
| Robert Baker | AVP & Mgr Microbiology & Molecular Biology | 40 | $178,064 | $0 | $11,002 | $189,066 | 1 |
| Ethan H Landesman | Director of Finance & Accounting | 40 | $162,407 | $0 | $2,735 | $165,142 | 1 |
| Glenn Miller | AVP & QA Manager | 40 | $152,751 | $0 | $8,811 | $161,562 | 1 |
| Theodore Francis | Manager IT & Cyber Security | 40 | $148,226 | $0 | $9,435 | $157,661 | 1 |
| Thomas Horn | Deputy Division Manager Toxicology | 40 | $143,246 | $0 | $8,938 | $152,184 | 1 |
| Tate W Brummitt | Director of Contracts & Procurement | 40 | $146,573 | $0 | $346 | $146,919 | 1 |
| Michael McGibbon | VP & Director for Administration | 40 | $105,813 | $0 | $6,621 | $112,434 | 1 |
| Rajagopal R Echambadi | Chairman & CEO | 1 | $0 | $0 | $0 | $0 | 1 |
| Walter Hazlitt | Secretary & Interim General Counsel | 1 | $0 | $0 | $0 | $0 | 2 |
| Angela Manning-Hardiman | Treasurer, VP Finance & CFO | 1 | $0 | $0 | $0 | $0 | 1 |
| Kenneth T Christensen | Interim Provost, SVP Academic Affairs & Member | 1 | $0 | $0 | $0 | $0 | 1 |
2019 · 15 people listed · 10 paid, $1.8M · 130 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| David McCormick | President | 40 | $314,790 | $0 | $18,950 | $333,740 | 1 |
| Miguel Muzzio | VP & Deputy Director, Mgr Analytical Chemistry | 40 | $174,188 | $0 | $10,667 | $184,855 | 1 |
| William Johnson | AVP & Manager Toxicology | 40 | $167,916 | $0 | $10,128 | $178,044 | 1 |
| Robert Baker | AVP & Mgr Microbiology & Molecular Biology | 40 | $163,702 | $0 | $10,281 | $173,983 | 1 |
| Narayanan Rajendran | VP & Mgr Inhalation Toxicology | 40 | $160,506 | $0 | $9,924 | $170,430 | 1 |
| Todd Bucciarelli | AVP & Business Development Manager | 40 | $153,667 | $0 | $9,438 | $163,105 | 1 |
| Michael McGibbon | VP & Director for Administration | 40 | $149,091 | $0 | $9,494 | $158,585 | 1 |
| Theodore Francis | Manager IT & Cyber Security | 40 | $146,997 | $0 | $9,088 | $156,085 | 1 |
| Glenn Miller | AVP & QA Manager | 40 | $143,758 | $0 | $8,565 | $152,323 | 1 |
| Thomas Horn | Deputy Division Manager Toxicology | 40 | $132,175 | $0 | $8,370 | $140,545 | 1 |
| Alan Cramb | Chairman, CEO & President | 1 | $0 | $0 | $0 | $0 | 7 |
| Anthony D'Amato | Secretary, VP & General Counsel | 1 | $0 | $0 | $0 | $0 | 3 |
| Michael D Horan | Treasurer, VP & CFO | 1 | $0 | $0 | $0 | $0 | 1 |
| Peter Kilpatrick | Member, Board of Governors | 1 | $0 | $0 | $0 | $0 | 2 |
| Mary Ellen Borchers | Interim VP of Finance | 1 | $0 | $0 | $0 | $0 | 1 |
Highest-paid independent contractors
2024 · 5 contractors · $3.9M
| Name | Location | Service | Paid |
|---|---|---|---|
| Charles River | Wilmington, MA | Pathology services | $3,035,000 |
| McCauley Mechanical Construction | Bridgeview, IL | Construction Services | $309,000 |
| Petrovic Enterprises | Downers Grove, IL | Construction Services | $287,000 |
| NeuroScience Associates Inc | Knoxville, TN | Pathology services | $151,000 |
| Marshall BioResources | North Rose, NY | Lab Animal Services | $145,000 |
2023 · 5 contractors · $9.5M
| Name | Location | Service | Paid |
|---|---|---|---|
| Charles River | Wilmington, MA | Pathology services | $4,332,000 |
| McCauley Mechanical Construction | Bridgeview, IL | Construction Services | $2,504,000 |
| WORLDWIDE PRIMATES INC | Miami, FL | Lab Animal Services | $1,824,000 |
| Petrovic Enterprises | Downers Grove, IL | Construction Services | $601,000 |
| Ridglan Farms Inc | Glenbeulah, WI | Lab Animal Services | $219,000 |
2022 · 5 contractors · $8.9M
| Name | Location | Service | Paid |
|---|---|---|---|
| McCauley Mechanical Construction | Bridgeview, IL | Construction Services | $4,538,000 |
| Charles River | Wilmington, MA | Pathology services | $3,014,000 |
| Petrovic Enterprises | Downers Grove, IL | Construction Services | $649,000 |
| Ridglan Farms Inc | Glenbeulah, WI | Lab Animal Services | $366,000 |
| STARLIMS Corporation | South Hollywood, FL | Clinical Reporting Services | $288,000 |
2021 · 5 contractors · $9.4M
| Name | Location | Service | Paid |
|---|---|---|---|
| McCauley Mechanical Construction | Bridgeview, IL | Construction Services | $4,049,000 |
| Charles River | Wilmington, MA | Pathology services | $3,021,000 |
| Petrovic Enterprises | Downers Grove, IL | Construction Services | $793,000 |
| Bear Construction Company | Rolling Meadows, IL | Construction Services | $792,000 |
| ENVIGO GLOBAL SERIVICES | Indianapolis, IN | Lab Services | $726,000 |
2020 · 5 contractors · $3.6M
| Name | Location | Service | Paid |
|---|---|---|---|
| Charles River | Wilmington, MA | Pathology services | $1,554,000 |
| Texas Biomedical Research | San Antonio, TX | Clinical Rptg Services | $1,321,000 |
| Triple F Farms Inc | Gillett, PA | Lab Animal Services | $246,000 |
| Ridglan Farms Inc | Blue Mounds, WI | Lab Animal Services | $246,000 |
| University of Oklahoma Health Science Ctr | Oklahoma City, OK | Clinical Reporting Services | $234,000 |
2019 · 5 contractors · $3.3M
| Name | Location | Service | Paid |
|---|---|---|---|
| Charles River | Wilmington, MA | Pathology services | $2,575,000 |
| University of Oklahoma Health Science Center | Oklahoma City, OK | Clinical Rptg Services | $234,000 |
| Messina Group Inc | Chicago, IL | Staffing services | $167,000 |
| Dust Em Clean Maintenance | Chicago, IL | Janitorial Services | $147,000 |
| Momentum Scientific Staffing | Chicago, IL | Staffing Services | $139,000 |
Paid as a vendor by
Other organizations that listed this one among their highest-paid independent contractors. Contractor lists give no EIN, so these are matched on name and address; check the filing.
| Year | Paid by | Service | Paid | Filing |
|---|---|---|---|---|
| 2018 | ACCESS TO ADVANCED HEALTH INSTITUTE | RESEARCH | $206,285 | view vendor page |
Who gave
Contributor names are not public for this form type.
Public charities filing Form 990 or 990-EZ report large donors on Schedule B, but the IRS withholds their names and addresses from public copies. Private foundations (990-PF) are different: their contributors are public.
Finances
Newest first. Each filing: its name on one row, its figures on the row beneath. Greyed filings are superseded by a later return for the same period and are left out everywhere else on this page.
| Revenue | Expenses | Assets | Net assets | Contributions | Program revenue | Officer pay | Employees | Volunteers |
|---|---|---|---|---|---|---|---|---|
| 2024 · Form 990 | ||||||||
| $17,520,000 | $23,019,000 | $36,279,000 | $24,890,000 | $0 | $17,444,000 | $1,689,000 | 128 | 0 |
| 2023 · Form 990 | ||||||||
| $28,657,000 | $27,336,000 | $42,170,000 | $30,391,000 | $0 | $28,520,000 | $1,858,000 | 127 | 0 |
| 2022 · Form 990 | ||||||||
| $27,838,000 | $25,988,000 | $43,645,000 | $28,943,000 | $0 | $27,749,000 | $2,758,000 | 157 | 0 |
| 2021 · Form 990 | ||||||||
| $29,871,000 | $25,493,000 | $44,213,000 | $27,015,000 | $0 | $29,810,000 | $1,505,000 | 152 | 0 |
| 2020 · Form 990 | ||||||||
| $29,119,000 | $25,975,000 | $42,081,000 | $22,800,000 | $0 | $29,028,000 | $1,933,000 | 150 | 0 |
| 2019 · Form 990 | ||||||||
| $26,941,000 | $25,017,000 | $32,512,000 | $19,626,000 | $0 | $26,793,000 | $799,000 | 130 | 0 |
Connected to
Organizations that list some of the same people on their returns (officers, directors, key employees on this organization’s latest return), and related organizations it lists on Schedule R.
- ILLINOIS INSTITUTE OF TECHNOLOGY Chicago, IL · 2 people in common (Jeremy Fine, Walter Hazlitt) · related organization (Schedule R)
Funders of this organization
4 grantors reported grants to this organization, $2,464,157 in all, tax years 2011 to 2021. Exact: the grantor wrote this organization's EIN. Fuzzy: the grantor wrote only a name (foundations' 990-PF has no EIN field), matched to the same or a near-identical name in the same state; the name as filed is shown. From the latest return for each grantor and year, so amended returns aren't counted twice. CSV
| Grantor | Total given | Grants | Latest year's amount | Latest year | Years given | Type | Match | Grants |
|---|---|---|---|---|---|---|---|---|
| UNIVERSITY OF CHICAGO | $2,222,643 | 7 | $41,914 | 2021 | 2014-2016, 2018-2021 | Public charity | Exact | show |
| UNITED NEGRO COLLEGE FUND INC | $147,058 | 3 | $34,979 | 2013 | 2011-2013 | Public charity | Exact | show |
| VANDERBILT UNIVERSITY | $70,456 | 2 | $35,228 | 2012 | 2011-2012 | Public charity | Exact | show |
| LEGACY GLOBAL FOUNDATION INC | $24,000 | 1 | $24,000 | 2016 | 2016 | DAF sponsor | Exact | show |
Nearby + Similar BETA
Organizations like this one: what they do and who they are linked to
Same category: NTEE code and revenue
Ranked without any AI: same NTEE code first, then the same NTEE group; then revenue within 2x, 5x or 10x; then the same state; then similar name and mission text. NTEE: the IRS’s code when it lists one, otherwise FURP’s inferred code. Same state only · More (100)
| Organization | State | NTEE | Latest revenue | Latest expenses | Top-paid title | Top pay | Why similar |
|---|---|---|---|---|---|---|---|
| INSTITUTE FOR CREATION RESEARCH | TX | U20 | $10,363,954 | $10,643,510 | PRESIDENT/TRUSTEE | $196,200 | Same NTEE code U20, revenue within 2x, similar name |
| WEST VIRGINIA STATE UNIVERSITY RESEARCH AND DEVELOPMENT CORP | WV | U20 | $21,949,840 | $21,431,082 | VICE CHAIR | $203,995 | Same NTEE code U20, revenue within 2x |
| CLIMATE CENTRAL INC | NJ | U20 | $22,272,608 | $11,535,677 | CEO & CHIEF SCIENTIST | $391,991 | Same NTEE code U20, revenue within 2x |
| SPARK NS INC | CA | U20 | $9,000,000 | $6,368,774 | EXECUTIVE DIRECTOR | $378,462 | Same NTEE code U20, revenue within 2x |
| UNIVERSITY LICENSE EQUITY HOLDINGS INC | CO | U20 | $19,670,419 | $2,218,535 | TREASURER/SECRETARY (THRU 05/24) | $686,410 | Same NTEE code U20, revenue within 2x |
| PATUXENT PARTNERSHIP INC | MD | U20 | $9,556,202 | $9,381,272 | IPA EMPLOYEE | $255,032 | Same NTEE code U20, revenue within 2x |
| ACADEMY OF MANAGED CARE PHARMACY A NEW JERSEY NONPROFIT CORPORATION | VA | U20 | $20,869,863 | $23,638,943 | Chief Executive Officer | $971,276 | Same NTEE code U20, revenue within 2x |
| ENERGETICS TECHNOLOGY CENTER INC | MD | U20 | $28,407,479 | $28,244,901 | President & COO | $291,608 | Same NTEE code U20, revenue within 2x |
| ST LOUIS SCIENCE CENTER FOUNDATION | MO | U20 | $10,815,081 | $9,659,434 | PRESIDENT / CEO (AS OF 2/25) | $373,441 | Same NTEE code U20, revenue within 2x |
| VIRGINIA HEALTH INFORMATION | VA | U20 | $13,708,032 | $11,975,971 | CHIEF EXECUTIVE OFFICER | $321,625 | Same NTEE code U20, revenue within 2x |
| FAJR SCIENTIFIC | TX | U20 | $18,174,508 | $13,201,857 | CEO | $230,000 | Same NTEE code U20, revenue within 2x |
| IQM RESEARCH INSTITUTE | MI | U20 | $4,600,511 | $4,561,763 | VP OF ADVANCE PROGRAMS | $333,281 | Same NTEE code U20, revenue within 5x, similar name |
| MIND RESEARCH INSTITUTE INC | CA | U20 | $5,670,095 | $7,550,544 | CHIEF EXECUTIVE OFFICER | $473,438 | Same NTEE code U20, revenue within 5x, similar name |
| NORTHWEST INSTITUTE OF RESEARCH INC | PA | U20 | $47,440,023 | $46,542,737 | CEO | $219,877 | Same NTEE code U20, revenue within 5x, similar name |
| SANTA FE INSTITUTE | NM | U20 | $51,822,371 | $16,973,641 | PRESIDENT | $472,082 | Same NTEE code U20, revenue within 5x |
| KANSAS HEALTH INSTITUTE | KS | U20 | $4,399,442 | $4,391,764 | PRESIDENT | $351,653 | Same NTEE code U20, revenue within 5x |
| BUCKMINSTER FULLER INSTITUTE | CA | U20 | $5,041,849 | $2,470,865 | Executive Dir. | $162,023 | Same NTEE code U20, revenue within 5x |
| SYSTEMS BUILDING RESEARCH ALLIANCE | NY | U20 | $4,930,518 | $1,447,014 | TREASURER/SECRETARY | $0 | Same NTEE code U20, revenue within 5x |
| OAK CREST INSTITUTE OF SCIENCE | CA | U20 | $6,470,203 | $6,314,850 | CEO | $248,539 | Same NTEE code U20, revenue within 5x |
| SOUTH CAROLINA RESEARCH FOUNDATION | SC | U20 | $5,271,618 | $5,122,804 | USC Dean, College of Pharmacy | $427,741 | Same NTEE code U20, revenue within 5x |
| AMERICAN FROZEN FOOD INSTITUTE | VA | U20 | $7,322,596 | $5,933,024 | President CEO | $706,162 | Same NTEE code U20, revenue within 5x |
| UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | TN | U20 | $8,519,357 | $9,874,862 | BOARD MEMBER | $0 | Same NTEE code U20, revenue within 5x |
| ASH REGISTRY INC | DC | U20 | $4,973,130 | $10,038,615 | EXECUTIVE DIRECTOR | $744,060 | Same NTEE code U20, revenue within 5x |
| HUMAN CELL ATLAS INC | MA | U20 | $5,842,219 | $5,540,729 | CO-CHAIR OF THE BOARD | $0 | Same NTEE code U20, revenue within 5x |
| PUBLIC ARCHAEOLOGY LABORATORY INC | RI | U20 | $8,365,042 | $7,937,630 | PRESIDENT | $288,934 | Same NTEE code U20, revenue within 5x |
Who funds organizations like this
Grantors that funded the 100 most similar organizations. Ranked by total given to them. Foundations (990-PF) and donor-advised fund sponsors only. Same matching as Funders above (by EIN, or by name for foundations).
The full list · all similar organizations
Where the money went
Every expense line on each return, biggest first: Form 990 Part IX (with its program, management and fundraising columns), 990-EZ Part I, or 990-PF Part I. Event marks lines the organization itself describes as events. “Events” in each summary adds those lines, conferences and meetings, and the direct costs of fundraising events. Unusual is not the same as improper. Many of these patterns have ordinary explanations. Check the filing.
2024 · Form 990 · $23,019,000 spent · pay $12,574,000 · grants $0 · events $36,000
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $8,728,000 | $6,635,000 | $2,093,000 | - | 37.9% | |
| Other (as described) | Subcontracts & Consultants | $2,773,000 | $2,745,000 | $28,000 | $0 | 12.0% |
| Depreciation and depletion | $2,122,000 | $1,884,000 | $238,000 | $0 | 9.2% | |
| Other (as described) | Lab-Operating Supplies & Services | $1,999,000 | $1,999,000 | $0 | $0 | 8.7% |
| Pay: officers, directors, trustees, key employees | $1,689,000 | $871,000 | $818,000 | - | 7.3% | |
| Occupancy | $1,269,000 | $1,073,000 | $196,000 | $0 | 5.5% | |
| Other employee benefits | $881,000 | $682,000 | $199,000 | - | 3.8% | |
| Payroll taxes | $717,000 | $538,000 | $179,000 | - | 3.1% | |
| Other (as described) | Bad Debt | $570,000 | $0 | $570,000 | $0 | 2.5% |
| Pension plan contributions | $559,000 | $442,000 | $117,000 | - | 2.4% | |
| Other (as described) | Repair and Maintenance | $339,000 | $11,000 | $328,000 | $0 | 1.5% |
| All other expenses | $333,000 | $62,000 | $271,000 | - | 1.4% | |
| Insurance | $263,000 | $0 | $263,000 | $0 | 1.1% | |
| Fees: legal | $157,000 | $0 | $157,000 | $0 | 0.7% | |
| Information technology | $132,000 | $99,000 | $33,000 | $0 | 0.6% | |
| Office expenses | $104,000 | $61,000 | $43,000 | $0 | 0.5% | |
| Fees: other services | $92,000 | $72,000 | $20,000 | $0 | 0.4% | |
| Interest | $91,000 | $0 | $91,000 | $0 | 0.4% | |
| Travel | $76,000 | $60,000 | $16,000 | $0 | 0.3% | |
| Fees: accounting | $74,000 | $0 | $74,000 | $0 | 0.3% | |
| Conferences, conventions and meetings | $36,000 | $22,000 | $14,000 | $0 | 0.2% | |
| Fees: investment management | $15,000 | $0 | $15,000 | $0 | 0.1% | |
| Total | $23,019,000 | 100% |
2023 · Form 990 · $27,336,000 spent · pay $13,183,000 · grants $0 · events $34,000
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $7,894,000 | $5,825,000 | $2,069,000 | $0 | 28.9% | |
| Other (as described) | Lab-Operating Supplies & Services | $5,033,000 | $5,033,000 | $0 | $0 | 18.4% |
| Other (as described) | Subcontracts & Consultants | $3,834,000 | $3,814,000 | $20,000 | $0 | 14.0% |
| Depreciation and depletion | $2,314,000 | $2,059,000 | $255,000 | $0 | 8.5% | |
| Other employee benefits | $1,968,000 | $1,496,000 | $472,000 | $0 | 7.2% | |
| Pay: officers, directors, trustees, key employees | $1,858,000 | $962,000 | $896,000 | $0 | 6.8% | |
| Occupancy | $1,447,000 | $1,167,000 | $280,000 | $0 | 5.3% | |
| Payroll taxes | $763,000 | $572,000 | $191,000 | $0 | 2.8% | |
| Pension plan contributions | $700,000 | $555,000 | $145,000 | $0 | 2.6% | |
| Fees: other services | $263,000 | $247,000 | $16,000 | $0 | 1.0% | |
| Insurance | $206,000 | - | $206,000 | $0 | 0.8% | |
| All other expenses | $206,000 | $147,000 | $59,000 | $0 | 0.8% | |
| Fees: legal | $174,000 | $0 | $174,000 | $0 | 0.6% | |
| Information technology | $131,000 | $131,000 | $0 | $0 | 0.5% | |
| Office expenses | $125,000 | $70,000 | $55,000 | $0 | 0.5% | |
| Interest | $122,000 | - | $122,000 | $0 | 0.4% | |
| Travel | $97,000 | $74,000 | $23,000 | $0 | 0.4% | |
| Fees: accounting | $84,000 | $0 | $84,000 | $0 | 0.3% | |
| Other (as described) | AR Writeoffs | $68,000 | $0 | $68,000 | $0 | 0.2% |
| Conferences, conventions and meetings | $34,000 | $20,000 | $14,000 | $0 | 0.1% | |
| Fees: investment management | $15,000 | - | $15,000 | $0 | 0.1% | |
| Total | $27,336,000 | 100% |
2022 · Form 990 · $25,988,000 spent · pay $13,099,000 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $6,556,000 | $5,268,000 | $1,288,000 | $0 | 25.2% | |
| Other (as described) | Lab-Operating Supplies & Services | $3,705,000 | $3,705,000 | $0 | $0 | 14.3% |
| Other (as described) | Subcontracts & Consultants | $3,023,000 | $2,955,000 | $68,000 | $0 | 11.6% |
| Pay: officers, directors, trustees, key employees | $2,758,000 | $2,206,000 | $552,000 | $0 | 10.6% | |
| Other employee benefits | $2,724,000 | $2,043,000 | $681,000 | $0 | 10.5% | |
| Depreciation and depletion | $2,694,000 | $2,480,000 | $214,000 | $0 | 10.4% | |
| Occupancy | $1,660,000 | $1,273,000 | $387,000 | $0 | 6.4% | |
| Payroll taxes | $728,000 | $546,000 | $182,000 | $0 | 2.8% | |
| Pension plan contributions | $333,000 | $250,000 | $83,000 | $0 | 1.3% | |
| Other (as described) | AR Writeoffs | $270,000 | $0 | $270,000 | $0 | 1.0% |
| Fees: other services | $262,000 | $243,000 | $19,000 | $0 | 1.0% | |
| Insurance | $251,000 | $27,000 | $224,000 | $0 | 1.0% | |
| Travel | $186,000 | $141,000 | $45,000 | $0 | 0.7% | |
| Information technology | $170,000 | $31,000 | $139,000 | - | 0.7% | |
| Office expenses | $155,000 | $53,000 | $102,000 | - | 0.6% | |
| Fees: legal | $151,000 | $0 | $151,000 | $0 | 0.6% | |
| All other expenses | $139,000 | $26,000 | $113,000 | $0 | 0.5% | |
| Interest | $128,000 | $0 | $128,000 | $0 | 0.5% | |
| Other (as described) | Employee Bonuses | $84,000 | $0 | $84,000 | $0 | 0.3% |
| Fees: investment management | $11,000 | $0 | $11,000 | $0 | 0.0% | |
| Total | $25,988,000 | 100% |
2021 · Form 990 · $25,493,000 spent · pay $11,694,000 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $6,935,000 | $5,548,000 | $1,387,000 | - | 27.2% | |
| Other (as described) | Lab-Operating Supplies & Services | $3,659,000 | $3,659,000 | $0 | $0 | 14.4% |
| Other (as described) | Subcontracts & Consultants | $3,088,000 | $3,053,000 | $35,000 | $0 | 12.1% |
| Depreciation and depletion | $2,534,000 | $2,072,000 | $462,000 | $0 | 9.9% | |
| Other employee benefits | $2,093,000 | $1,570,000 | $523,000 | - | 8.2% | |
| Occupancy | $1,526,000 | $1,315,000 | $211,000 | - | 6.0% | |
| Pay: officers, directors, trustees, key employees | $1,505,000 | $1,204,000 | $301,000 | - | 5.9% | |
| Other (as described) | Employee Bonus | $853,000 | $611,000 | $242,000 | $0 | 3.3% |
| Payroll taxes | $745,000 | $559,000 | $186,000 | - | 2.9% | |
| Other (as described) | A/R Writeoff | $705,000 | $0 | $705,000 | $0 | 2.8% |
| Pension plan contributions | $416,000 | $312,000 | $104,000 | $0 | 1.6% | |
| All other expenses | $249,000 | $115,000 | $134,000 | - | 1.0% | |
| Fees: other services | $245,000 | $225,000 | $20,000 | - | 1.0% | |
| Information technology | $226,000 | $18,000 | $208,000 | - | 0.9% | |
| Insurance | $209,000 | $0 | $209,000 | $0 | 0.8% | |
| Travel | $143,000 | $116,000 | $27,000 | - | 0.6% | |
| Fees: legal | $142,000 | - | $142,000 | - | 0.6% | |
| Fees: accounting | $88,000 | - | $88,000 | - | 0.3% | |
| Office expenses | $73,000 | $46,000 | $27,000 | - | 0.3% | |
| Interest | $48,000 | $0 | $48,000 | $0 | 0.2% | |
| Fees: investment management | $11,000 | - | $11,000 | - | 0.0% | |
| Total | $25,493,000 | 100% |
2020 · Form 990 · $25,975,000 spent · pay $11,219,000 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $6,325,000 | $5,091,000 | $1,234,000 | $0 | 24.4% | |
| Other (as described) | Subcontractors & Consultants | $4,716,000 | $4,669,000 | $47,000 | $0 | 18.2% |
| Other (as described) | Lab-Operating Supplies & Services | $4,249,000 | $4,249,000 | $0 | $0 | 16.4% |
| Pay: officers, directors, trustees, key employees | $1,933,000 | $1,556,000 | $377,000 | - | 7.4% | |
| Depreciation and depletion | $1,886,000 | $1,411,000 | $475,000 | $0 | 7.3% | |
| Other employee benefits | $1,880,000 | $1,410,000 | $470,000 | - | 7.2% | |
| Occupancy | $1,510,000 | $1,267,000 | $243,000 | $0 | 5.8% | |
| Other (as described) | Employee Bonuses | $687,000 | $509,000 | $178,000 | $0 | 2.6% |
| Payroll taxes | $671,000 | $503,000 | $168,000 | $0 | 2.6% | |
| Pension plan contributions | $410,000 | $308,000 | $102,000 | $0 | 1.6% | |
| Fees: other services | $409,000 | $319,000 | $90,000 | - | 1.6% | |
| All other expenses | $282,000 | $17,000 | $265,000 | $0 | 1.1% | |
| Other (as described) | AR Writeoffs | $195,000 | $0 | $195,000 | $0 | 0.8% |
| Travel | $177,000 | $158,000 | $19,000 | $0 | 0.7% | |
| Insurance | $171,000 | $0 | $171,000 | $0 | 0.7% | |
| Fees: legal | $140,000 | $0 | $140,000 | $0 | 0.5% | |
| Information technology | $130,000 | $37,000 | $93,000 | - | 0.5% | |
| Fees: accounting | $117,000 | $0 | $117,000 | $0 | 0.5% | |
| Office expenses | $76,000 | $76,000 | $0 | $0 | 0.3% | |
| Fees: investment management | $11,000 | $0 | $11,000 | $0 | 0.0% | |
| Total | $25,975,000 | 100% |
2019 · Form 990 · $25,017,000 spent · pay $10,871,000 · grants $0 · events $8,000
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $6,831,000 | $5,119,000 | $1,712,000 | $0 | 27.3% | |
| Other (as described) | Subcontractors & consultants | $5,291,000 | $5,285,000 | $6,000 | $0 | 21.1% |
| Other (as described) | Lab-Operating supplies & services | $4,066,000 | $3,688,000 | $378,000 | $0 | 16.3% |
| Other employee benefits | $2,185,000 | $1,638,000 | $547,000 | $0 | 8.7% | |
| Occupancy | $1,942,000 | $1,859,000 | $83,000 | $0 | 7.8% | |
| Depreciation and depletion | $1,559,000 | $1,308,000 | $251,000 | $0 | 6.2% | |
| Pay: officers, directors, trustees, key employees | $799,000 | $649,000 | $150,000 | $0 | 3.2% | |
| Payroll taxes | $626,000 | $469,000 | $157,000 | $0 | 2.5% | |
| Pension plan contributions | $430,000 | $322,000 | $108,000 | $0 | 1.7% | |
| Other (as described) | Employee bonuses | $430,000 | $357,000 | $73,000 | $0 | 1.7% |
| Other (as described) | AR writeoffs | $184,000 | $184,000 | $0 | $0 | 0.7% |
| Insurance | $140,000 | $0 | $140,000 | $0 | 0.6% | |
| Fees: legal | $139,000 | $0 | $139,000 | $0 | 0.6% | |
| Fees: accounting | $128,000 | $0 | $128,000 | $0 | 0.5% | |
| Travel | $91,000 | $62,000 | $29,000 | $0 | 0.4% | |
| Interest | $77,000 | $0 | $77,000 | $0 | 0.3% | |
| All other expenses | $72,000 | $50,000 | $22,000 | $0 | 0.3% | |
| Fees: investment management | $19,000 | $0 | $19,000 | $0 | 0.1% | |
| Conferences, conventions and meetings | $8,000 | $6,000 | $2,000 | $0 | 0.0% | |
| Total | $25,017,000 | 100% |
Federal grants and contracts
Awards from USAspending.gov to a recipient with this organization's name and zip code. Obligations by federal fiscal year (October to September); each award links to its page on usaspending.gov.
| Fiscal year | Grants and other assistance | Contracts | Awards |
|---|---|---|---|
| 2026 | $0 | $3,215,119 | 17 |
| 2025 | $0 | $1,073,258 | 21 |
| 2024 | $0 | $5,250,429 | 24 |
| 2023 | $0 | $4,542,522 | 23 |
| 2022 | $0 | $2,930,476 | 34 |
| 2021 | $0 | $4,431,013 | 21 |
| 2020 | -$4,607 | $4,115,917 | 25 |
| 2019 | $0 | $2,594,500 | 30 |
| 2018 | $0 | $8,856,293 | 25 |
| 2017 | $0 | $8,692,569 | 31 |
| 2016 | $0 | $9,878,306 | 29 |
| 2015 | $0 | $8,356,143 | 22 |
| 2014 | $453,776 | $2,003,016 | 13 |
| 2013 | $438,848 | $5,002,973 | 21 |
| 2012 | $465,889 | $27,425,203 | 36 |
| 2011 | $464,897 | $76,268,561 | 62 |
| 2010 | $374,940 | $138,550,387 | 64 |
| 2009 | $474,697 | $106,486,899 | 71 |
| 2008 | $166,995 | $60,558,805 | 119 |
| 2007 | $466,574 | $50,498,292 | 78 |
Largest awards · 200 shown
| Year | Agency | Kind | Program | Description | Obligated |
|---|---|---|---|---|---|
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | TASK ORDER AWARD- SSL GLP AND NON-GLP TOXICOLOGY STUDIES | $3,391,980 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $559,996 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IITRI - PA1 TASK ORDER #07 | $108,506 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | TOXICOLOGY STUDIES IN MICE ADMINISTERED MTX-531 - FINAL DELIVERABLES | $68,323 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | TOXICOLOGY STUDIES IN RATS AND DOGS ADMINISTERED AIT-102 | $59,725 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IITRI - 2026 SF IND-ENABLING GLP TOXICOLOGY STUDIES | $46,385 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IITRI - PERFORMANCE AREA 1 TO2 | $45,779 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | FIRST-IN-CLASS SMALL MOLECULE CANDIDATE NCGC72 (CD206 AGONIST) FOR IMMUNOLOGICALLY COLD SOLID ORGAN CANCERS | $34,740 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXER | -$96 |
| 2026 | National Institutes of Health | Contract | OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES 541690 | IGF::OT::IGF NEXT PRECLINICAL TOXICOLOGY&PHARMACOLOGY OF DRUGS DEVELOPED FOR CANCER PATIENTS, TO#3, EXPLORATORY STUDIES OF CCR4 CART CELLS | -$91,999 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. | -$1,008,219 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | TOXICOLOGY STUDIES IN MICE AND DOGS ADMINISTERED MTX-531 | $451,034 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | PTTP TASK ORDER - IITRI - MS RODENT AND NON-RODENT MTD-DRF STUDIES | $401,373 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IITRI - PTTP DRF BPN STUDY - TO3 | $218,025 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IITRI - PERFORMANCE AREA 1 TO2 | $84,588 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $50,726 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $10,025 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF | -$6,373 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | -$6,708 |
| 2025 | Office of Assistant Secretary for Preparedness and Response | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF | -$129,432 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | TOXICOLOGY STUDIES IN MICE AND DOGS ADMINISTERED MTX-531 | $1,339,008 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF | $1,020,618 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $676,144 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | TOXICOLOGY STUDIES IN RATS AND DOGS ADMINISTERED AIT-102 | $568,068 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | FIRST-IN-CLASS SMALL MOLECULE CANDIDATE NCGC72 (CD206 AGONIST) FOR IMMUNOLOGICALLY COLD SOLID ORGAN CANCERS | $512,266 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IITRI -DOG MTD-DRF STUDIES-TO 4 | $224,716 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IITRI - PTTP DRF BPN STUDY - TO3 | $220,123 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IITRI - NON-GLP DOSE RANGE FINDING (DRF) STUDIES-DEC. 2023 #2 | $201,969 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $154,317 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $143,468 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $115,334 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IITRI - PERFORMANCE AREA 1 TO2 | $82,128 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXER | $36,192 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | EVALUATION OF AFPEP FOR THE PREVENTION OF BREAST CANCER | -$2,780 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | GLP 28 DAY TOXICITY STUDY OF ACT-1 WHEN APPLIED TOPICALLY TO EYES TWICE DAILY FOR 28 DAYS IN DOGS WITH A 14 DAY RECOVERY PERIOD. POP: 09/01/2019 TO 02/29/2020. | -$2,907 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | BASE TITLE: PREVENT PRECLINICAL PHARMACOLOGY AND TOXICOLOGY TASK ORDER TITLE: NICOTINE REDUCTION THERAPY USING THE HUMAN MONOCLONAL ANTIBODY ATI-1013 | -$2,912 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF ACOZIBOROLE (SCYX-7158) TO SUPPORT HUMAN AFRICAN TRYPANOSOMIASIS (HAT OR "SLEEPING SICKNESS"). POP: 09/01/2019 TO 08/31/2020. | -$35,320 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $1,456,819 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. | $1,425,732 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | BASE TITLE: PREVENT PRECLINICAL PHARMACOLOGY AND TOXICOLOGY TASK ORDER TITLE: NICOTINE REDUCTION THERAPY USING THE HUMAN MONOCLONAL ANTIBODY ATI-1013 | $659,489 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $644,637 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXER | $418,720 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $224,185 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $201,709 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF COVALENT BI-TOX TO SUPPORT NEUROPATHIC PAIN INDICATION | $22,262 |
| 2023 | Food and Drug Administration | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IGF::OT::IGF, IN VIVO TOXICOLOGY OF TOBACCO AND RELATED PRODUCTS | -$1,000 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IIT RESCH INSTITUTE:1107221 [18-005715] TO PERFORM THE STUDY "SINGLE PO DOSE CARDIOVASCULAR AND PULMONARY SAFETY PHARMACOLOGY STUDY OF METARRESTIN IN TELEMETERE | -$9,390 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | TO ISSUE TASK ORDER HHSN27200001, TASK AREA F, BASE IDIQ CONTRACT KICK-OFF | -$23,800 |
| 2023 | Department of the Army | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUSTAINMENT AND MAINTENANCE OF BIOSURETY | -$40,073 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IIT RESEARCH INSTITUTE:1107221 [18-004523] | -$55,529 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF BPN14770 TO SUPPORT PEDIATRIC POPULATION WITH FRAGILE X SYNDROME | -$112,474 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IIT RESEARCH INSTITUTE:1107221 | -$268,762 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | PRECLINICAL MICROBIOLOGICAL, SAFETY, TOXICOLOGY, AND PHARMACOKINETIC SERVICES | $1,883,524 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $750,000 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF COVALENT BI-TOX TO SUPPORT NEUROPATHIC PAIN INDICATION | $743,733 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $698,273 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF | $291,405 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $207,287 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $156,564 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. | $10,092 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | CONTRACT ORIENTATION & KICKOFF MEETING FOR R&D SERVICES UNDER "PRECLINICAL TOXICOLOGY OF SMALL MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS" | $3,000 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | "CONTRACT ORIENTATION AND KICKOFF MEETING", TASK ORDER #1 UNDER 75N91019D00012. TASK ORDER PERIOD OF PERFORMANCE: 1/25/2019-2/24/2019. | -$1,101 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | "CONTRACT ORIENTATION AND KICKOFF MEETING" UNDER CONTRACT 75N91019D00013 | -$1,101 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF HHSN2612015000241 PERIOD OF PERFORMANCE: 9/15/16 TO 10/14/2018 PRECLINICAL EVALUATION OF A NEW LIPID-BASED SMEDDS | -$1,870 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | PRECLINICAL EFFICACY EVALUATION OF THE LIPID-BASED SMEDDS FORMULATION OF DIM, BR-9001, TO AWARD 3 | -$2,942 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IGF::OT::IGF TASK ORDER AWARD FOR "NON-CLINICAL SAFETY ASSESSMENT OF SPIF TO SUPPORT CHRONIC GVHD INDICATION" TO IIT RESEARCH INSTITUTE | -$301,031 |
| 2022 | Department of the Army | Contract | TESTING LABORATORIES 541380 | TECHNLOLOGY TRANSFER ASSAYS | -$334,926 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUPPORT FOR ENDOXIFEN GEL CLINICAL DEVELOPMENT | -$524,909 |
| 2022 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF ASPR-16-05523 -- TASK ORDER TO IITRI UNDER RTOR BIO-0023 FOR PRODUCTION OF ZIKA VIRUS REGENTS AND ASSAYS | -$645,519 |
| 2021 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $1,834,370 |
| 2021 | Department of the Army | Contract | TESTING LABORATORIES 541380 | TECHNLOLOGY TRANSFER ASSAYS | $981,000 |
| 2021 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXER | $844,172 |
| 2021 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | EVALUATION OF AFPEP FOR THE PREVENTION OF BREAST CANCER | $535,343 |
| 2021 | National Institutes of Health | Contract | OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES 541690 | IGF::OT::IGF NEXT PRECLINICAL TOXICOLOGY&PHARMACOLOGY OF DRUGS DEVELOPED FOR CANCER PATIENTS, TO#3, EXPLORATORY STUDIES OF CCR4 CART CELLS | $238,571 |
| 2021 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | CONTRACT KICK-OFF MEETING FOR NINDS PHARMACOLOGY AND TOXICOLOGY FOR THERAPEUTICS PROGRAM (PTTP) | $1,523 |
| 2021 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TAS::75 0849::TAS PRECLINICAL TOXICOLOGY STUDIES | -$3,965 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $1,798,575 |
| 2020 | Office of Assistant Secretary for Preparedness and Response | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF | $637,420 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | COVID-19 RELATED STUDY INVOLVING DOGS | $597,893 |
| 2020 | National Institutes of Health | Contract | OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES 541690 | SUPPORT FOR THE PRECLINICAL DEVELOPMENT OF EIF4A INHIBITORS ROCAGLAMIDE AND DIDESMETHYLROCAGLAMIDE. (TOXICIOLOGY SERVICES TO SUPPORT PRECLINICAL DRUG DEVELOPMEN | $588,615 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF | $430,361 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. | $323,766 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $213,180 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $153,392 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | GLP 28 DAY TOXICITY STUDY OF ACT-1 WHEN APPLIED TOPICALLY TO EYES TWICE DAILY FOR 28 DAYS IN DOGS WITH A 14 DAY RECOVERY PERIOD. POP: 09/01/2019 TO 02/29/2020. | $109,619 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IGF::OT::IGF TASK ORDER AWARD FOR "NON-CLINICAL SAFETY ASSESSMENT OF SPIF TO SUPPORT CHRONIC GVHD INDICATION" TO IIT RESEARCH INSTITUTE | $94,590 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF ACOZIBOROLE (SCYX-7158) TO SUPPORT HUMAN AFRICAN TRYPANOSOMIASIS (HAT OR "SLEEPING SICKNESS"). POP: 09/01/2019 TO 08/31/2020. | $87,787 |
| 2020 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF | $84,134 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF CONTRACT ORIENTATION KICKOFF MEETING PP: 9/22/2015 TO 12/31/2015 | -$703 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF NOVEL ANDROGEN RECEPTOR ANTAGONIST-MEDIATED CHEMOPREVENTION OF PROSTATE CANCER | -$2,374 |
| 2020 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | DEGUELIN IN THERAPY OF TRIPLE NEGATIVE BREAST CANCER | -$4,607 |
| 2020 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF | -$5,136 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TAS::75 0849::TAS PRECLINICAL TOXICOLOGY STUDIES | -$11,950 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | STUDIES TO EVALUATE TOXIC AND CARCINOGENIC POTENTIAL OF CELL PHONE RADIO FREQUENCY RADIATION IN LAB ANIMALS FOR NTP | -$441,130 |
| 2020 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUPPORT FOR THE AEROSOL DEVELOPMENT OF BEXAROTENE HHSN2612015000240 TO: HHSN26100004 POP: 9/18/2017 TO 9/17/2019 | -$542,120 |
| 2019 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF ACOZIBOROLE (SCYX-7158) TO SUPPORT HUMAN AFRICAN TRYPANOSOMIASIS (HAT OR "SLEEPING SICKNESS"). POP: 09/01/2019 TO 08/31/2020. | $1,103,699 |
| 2019 | Office of Assistant Secretary for Preparedness and Response | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF | $726,471 |
| 2019 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | GLP 28 DAY TOXICITY STUDY OF ACT-1 WHEN APPLIED TOPICALLY TO EYES TWICE DAILY FOR 28 DAYS IN DOGS WITH A 14 DAY RECOVERY PERIOD. POP: 09/01/2019 TO 02/29/2020. | $440,911 |
| 2019 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IGF::OT::IGF TASK ORDER AWARD FOR "NON-CLINICAL SAFETY ASSESSMENT OF SPIF TO SUPPORT CHRONIC GVHD INDICATION" TO IIT RESEARCH INSTITUTE | $193,902 |
| 2019 | Office of Assistant Secretary for Preparedness and Response | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF | $122,161 |
| 2019 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUPPORT FOR THE AEROSOL DEVELOPMENT OF BEXAROTENE HHSN2612015000240 TO: HHSN26100004 POP: 9/18/2017 TO 9/17/2019 | $56,577 |
| 2019 | National Institutes of Health | Contract | OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES 541690 | THREE RABBIT STUDY: (1) DOSE RANGE FINDING STUDY IN RABBITS VIA ORAL GAVAGE (NON-GLP); (2) PRELIMINARY EMBRYO FETAL DEVELOPMENTAL STUDY IN RABBITS VIA ORAL GAVA | $51,961 |
| 2019 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | "CONTRACT ORIENTATION AND KICKOFF MEETING" UNDER CONTRACT 75N91019D00013 | $3,500 |
| 2019 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | "CONTRACT ORIENTATION AND KICKOFF MEETING", TASK ORDER #1 UNDER 75N91019D00012. TASK ORDER PERIOD OF PERFORMANCE: 1/25/2019-2/24/2019. | $3,500 |
| 2019 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TAS::75 0849::TAS PRECLINICAL TOXICOLOGY STUDIES | $0 |
| 2019 | Food and Drug Administration | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IGF::OT::IGF EFFECTS OF MENTHOL ON ACROLEIN AND CIGARETTE INDUCED LUNG INFLAMMATION | -$108,181 |
| 2018 | Office of Assistant Secretary for Preparedness and Response | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF | $1,840,630 |
| 2018 | Office of Assistant Secretary for Preparedness and Response | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF | $1,801,910 |
| 2018 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IIT RESEARCH INSTITUTE:1107221 | $1,181,940 |
| 2018 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | PRECLINICAL EFFICACY EVALUATION OF THE LIPID-BASED SMEDDS FORMULATION OF DIM, BR-9001, TO AWARD 3 | $973,931 |
| 2018 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | NON-CLINICAL SAFETY ASSESSMENT OF BPN14770 TO SUPPORT PEDIATRIC POPULATION WITH FRAGILE X SYNDROME | $902,296 |
| 2018 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXER | $685,688 |
| 2018 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF | $437,166 |
| 2018 | National Institutes of Health | Contract | OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES 541690 | THREE RABBIT STUDY: (1) DOSE RANGE FINDING STUDY IN RABBITS VIA ORAL GAVAGE (NON-GLP); (2) PRELIMINARY EMBRYO FETAL DEVELOPMENTAL STUDY IN RABBITS VIA ORAL GAVA | $435,576 |
| 2018 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IIT RESEARCH INSTITUTE:1107221 [18-004523] | $327,018 |
| 2018 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IIT RESCH INSTITUTE:1107221 [18-005715] TO PERFORM THE STUDY "SINGLE PO DOSE CARDIOVASCULAR AND PULMONARY SAFETY PHARMACOLOGY STUDY OF METARRESTIN IN TELEMETERE | $139,483 |
| 2018 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF HHSN2612015000241 PERIOD OF PERFORMANCE: 9/15/16 TO 10/14/2018 PRECLINICAL EVALUATION OF A NEW LIPID-BASED SMEDDS | $60,976 |
| 2018 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF | $43,888 |
| 2018 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | TO ISSUE TASK ORDER HHSN27200001, TASK AREA F, BASE IDIQ CONTRACT KICK-OFF | $26,424 |
| 2018 | National Institutes of Health | Contract | OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES 541690 | IGF::OT::IGF NCCIH STUDY ON REPRODUCTIVE TOXICOLOGY STUDIES IN RATS (POTS 16-000765) | $20,898 |
| 2018 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF EVALUATION OF INOS ANTAGONISTS IN THE PREVENTION OF ORAL CANCER | -$22 |
| 2018 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF CHEMOPREVENTION OF PROSTATE CANCER VIA ESTROGEN RECEPTOR BETA AGONISTS | -$845 |
| 2018 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IIT RESEARCH INSTITUTE - DEVELOPMENT OF ANIMAL MODELS TO MEET THE THREATS OF CBRN AGENTS, INFLUENZA, AND EMERGING INFECTIOUS DISEASES IN SUPPORT OF THE PREPARED | -$20,661 |
| 2017 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUPPORT FOR THE AEROSOL DEVELOPMENT OF BEXAROTENE HHSN2612015000240 TO: HHSN26100004 POP: 9/18/2017 TO 9/17/2019 | $2,597,086 |
| 2017 | Department of the Army | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUSTAINMENT AND MAINTENANCE OF BIOSURETY | $1,655,784 |
| 2017 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IGF::OT::IGF TASK ORDER AWARD FOR "NON-CLINICAL SAFETY ASSESSMENT OF SPIF TO SUPPORT CHRONIC GVHD INDICATION" TO IIT RESEARCH INSTITUTE | $1,582,504 |
| 2017 | Food and Drug Administration | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IGF::OT::IGF INHALATION STUDY OF THE IN VIVO TOXICITY OF ESSENTIAL OILS | $1,574,100 |
| 2017 | National Institutes of Health | Contract | OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES 541690 | IGF::OT::IGF NEXT PRECLINICAL TOXICOLOGY&PHARMACOLOGY OF DRUGS DEVELOPED FOR CANCER PATIENTS, TO#3, EXPLORATORY STUDIES OF CCR4 CART CELLS | $479,694 |
| 2017 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF ASPR-16-05523 -- TASK ORDER TO IITRI UNDER RTOR BIO-0023 FOR PRODUCTION OF ZIKA VIRUS REGENTS AND ASSAYS | $267,874 |
| 2017 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUPPORT FOR ENDOXIFEN GEL CLINICAL DEVELOPMENT | $174,815 |
| 2017 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | TAS::75 0886::TAS ANIMAL MODELS OF INFECTIOUS DISEASES | $100,000 |
| 2017 | Department of the Navy | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF AEROSOL GENERATION SYSTEM SETUP PR# 61-0005-17 | $89,930 |
| 2017 | National Institutes of Health | Contract | TESTING LABORATORIES 541380 | IGF::OT::IGF VACCINE EFFICACY IN THE MOUSE MODEL OF H7 INFLUENZA INFECTION | $79,500 |
| 2017 | Department of the Army | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUSTAINMENT AND MAINTENANCE OF BIOSURETY | $71,243 |
| 2017 | Office of Assistant Secretary for Preparedness and Response | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IIT RESEARCH INSTITUTE (TS) - IDIQ FOR BIOLOGICAL NONCLINICAL SERVICES IGF::OT::IGF | $50,000 |
| 2017 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | TAS::75 0885::TAS ANIMAL MODELS OF INFECTIOUS DISEASES | $50,000 |
| 2017 | Office of Assistant Secretary for Preparedness and Response | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IIT RESEARCH INSTITUTE (AS) - IDIQ FOR BIOLOGICAL NONCLINICAL SERVICES IGF::OT::IGF | $50,000 |
| 2017 | Office of Assistant Secretary for Preparedness and Response | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IIT RESEARCH INSTITUTE (AMT) - IDIQ FOR BIOLOGICAL NONCLINICAL SERVICES IGF::OT::IGF | $50,000 |
| 2017 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF | $9,889 |
| 2017 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF NONCLINICAL SAFETY, TOXICOKINETIC, AND STABILITY EVALUATION OF BIORESPONSE DIINDOLYLMETHANE VAGINAL CREAM FOR TOPICAL TREATMENT CERVICAL INTRAEPITH | -$553 |
| 2017 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | BIOMEDICAL (APPLIED/EXPLORATORY) | -$74,938 |
| 2017 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TAS::75 0849::TAS PRECLINICAL TOXICOLOGY STUDIES | -$114,356 |
| 2016 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF | $2,183,016 |
| 2016 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF ASPR-16-05523 -- TASK ORDER TO IITRI UNDER RTOR BIO-0023 FOR PRODUCTION OF ZIKA VIRUS REGENTS AND ASSAYS | $1,540,596 |
| 2016 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUPPORT FOR ENDOXIFEN GEL CLINICAL DEVELOPMENT | $1,531,900 |
| 2016 | Department of the Army | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUSTAINMENT AND MAINTENANCE OF BIOSURETY | $1,402,616 |
| 2016 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF FOR OTHER FUNCTIONS | $1,007,222 |
| 2016 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF | $987,845 |
| 2016 | National Institutes of Health | Contract | OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES 541690 | IGF::OT::IGF NCCIH STUDY ON REPRODUCTIVE TOXICOLOGY STUDIES IN RATS (POTS 16-000765) | $610,874 |
| 2016 | Food and Drug Administration | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IGF::OT::IGF EFFECTS OF MENTHOL ON ACROLEIN AND CIGARETTE INDUCED LUNG INFLAMMATION | $465,680 |
| 2016 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF HHSN2612015000241 PERIOD OF PERFORMANCE: 9/15/16 TO 10/14/2018 PRECLINICAL EVALUATION OF A NEW LIPID-BASED SMEDDS | $262,005 |
| 2016 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TAS::75 0849::TAS PRECLINICAL TOXICOLOGY STUDIES | $61,056 |
| 2016 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF IIT RESCH INSTITUTE:1107221 [16-053307] | $16,200 |
| 2016 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | BIOMEDICAL (APPLIED/EXPLORATORY) | $8,415 |
| 2016 | National Institutes of Health | Contract | OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES 541690 | IGF::OT::IGF TO#1 PRE-CLIN TOX STUDY OF DRUG DEV FOR CANCER PATIENTS HHSN261201600015I DTP-16-054 TPB | $4,145 |
| 2016 | National Institutes of Health | Contract | ALL OTHER PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES 541990 | IGF::OT::IGF KICK OFF MEETING, PRECLINICAL PHARMACOKINETIC&PHARMACOLOGY EVALUATIONS OF AGENTS BEING DEVELOPED FOR CANCER PATIENTS, 7/1/2016 - 9/30/16 | $1,010 |
| 2016 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | PRECLINICAL TOXICOLOGY AND PHARMACOLOGY OF DRUGS | -$26,281 |
| 2016 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | STUDIES TO EVALUATE TOXIC AND CARCINOGENIC POTENTIAL OF CELL PHONE RADIO FREQUENCY RADIATION IN LAB ANIMALS FOR NTP | -$177,992 |
| 2015 | National Institutes of Health | Contract | 541710 | STUDIES TO EVALUATE TOXIC AND CARCINOGENIC POTENTIAL OF CELL PHONE RADIO FREQUENCY RADIATION IN LAB ANIMALS FOR NTP | $3,549,647 |
| 2015 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF FOR OTHER FUNCTIONS | $2,219,193 |
| 2015 | Department of the Army | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUSTAINMENT AND MAINTENANCE OF BIOSURETY | $1,415,081 |
| 2015 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF NOVEL ANDROGEN RECEPTOR ANTAGONIST-MEDIATED CHEMOPREVENTION OF PROSTATE CANCER | $598,583 |
| 2015 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF | $570,858 |
| 2015 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TAS::75 0849::TAS PRECLINICAL TOXICOLOGY STUDIES | $236,727 |
| 2015 | Office of Assistant Secretary for Preparedness and Response | Contract | BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING 325414 | IGF::OT::IGF FOR OTHER FUNCTIONS PROJECT: EFFICACY STUDIES OF AB103 AGAINST LETHAL CHALLENGE OF STAPHYLOCOCCAL ENTEROTOXIN B (SEB) IN C3H/HEJ MICE | $128,233 |
| 2015 | National Institutes of Health | Contract | ALL OTHER PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES 541990 | NCATS IIT RESEARCH DOSE RANGE FINDING IN MICE IGF::CL::IGF | $119,495 |
| 2015 | National Institutes of Health | Contract | 541710 | BIOMEDICAL (APPLIED/EXPLORATORY) | $25,410 |
| 2015 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF CONTRACT ORIENTATION KICKOFF MEETING PP: 9/22/2015 TO 12/31/2015 | $4,520 |
| 2015 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF CONTRACT ORIENTATION AND KICKOFF MEETING 9/30 TO 12/31/2015 | $1,024 |
| 2015 | Food and Drug Administration | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | IGF::OT::IGF, IN VIVO TOXICOLOGY OF TOBACCO AND RELATED PRODUCTS | $1,000 |
| 2015 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | TAS::75 0885::TAS ANIMAL MODELS OF INFECTIOUS DISEASES | -$50,000 |
| 2015 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | TAS::75 0886::TAS ANIMAL MODELS OF INFECTIOUS DISEASES | -$100,000 |
| 2015 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | PRECLINICAL TOXICOLOGY AND PHARMACOLOGY OF DRUGS | -$363,627 |
| 2014 | Department of the Army | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF SUSTAINMENT AND MAINTENANCE OF BIOSURETY | $1,403,327 |
| 2014 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TAS::75 0849::TAS PRECLINICAL TOXICOLOGY STUDIES | $924,326 |
| 2014 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | DEGUELIN IN THERAPY OF TRIPLE NEGATIVE BREAST CANCER | $453,776 |
| 2014 | Department of the Army | Contract | 541710 | 200211!000732!2100!MD17 !US ARMY MEDICAL RESEARCH ACQ ACT!DAMD1702C0101 !A!N! !N! !20020604!20041130!005447826!005447826!005447826!N!IIT RES | $8,722 |
| 2014 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | PRECLINICAL PHARMACOLOGY AND TOXICOLOGY STUDIES | $0 |
| 2014 | National Institutes of Health | Contract | OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES 541690 | TAS::75 0886::TAS NON-HUMAN PRIMATE STUDY FOR FDA REGULATORY APPROVAL TO BEGIN HUMAN TRIALS | -$333,358 |
| 2013 | Department of the Air Force | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | TECHNICAL AREA TASKS | $930,861 |
| 2013 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) 541712 | TAS::75 0849::TAS PRECLINICAL TOXICOLOGY STUDIES | $885,185 |
| 2013 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF CHEMOPREVENTION OF PROSTATE CANCER VIA ESTROGEN RECEPTOR BETA AGONISTS | $686,259 |
| 2013 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF EVALUATION OF INOS ANTAGONISTS IN THE PREVENTION OF ORAL CANCER | $621,261 |
| 2013 | Department of the Air Force | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | TECHNICAL AREA TASKS | $495,050 |
| 2013 | National Institutes of Health | Contract | 541710 | STUDIES TO EVALUATE TOXIC AND CARCINOGENIC POTENTIAL OF CELL PHONE RADIO FREQUENCY RADIATION IN LAB ANIMALS FOR NTP | $465,060 |
| 2013 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | DEGUELIN IN THERAPY OF TRIPLE NEGATIVE BREAST CANCER | $438,848 |
| 2013 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | PRECLINICAL IN VITRO AND IN VIVO SCREENING ASSAYS FOR CANCER PREVENTIVE AGENT DEVELOPMENT | $425,100 |
| 2013 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | PRECLINICAL PHARMACOLOGY AND TOXICOLOGY STUDIES | $245,283 |
| 2013 | Department of the Air Force | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | TECHNICAL AREA TASKS | $231,151 |
| 2013 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | IGF::OT::IGF NONCLINICAL SAFETY, TOXICOKINETIC, AND STABILITY EVALUATION OF BIORESPONSE DIINDOLYLMETHANE VAGINAL CREAM FOR TOPICAL TREATMENT CERVICAL INTRAEPITH | $165,842 |
| 2013 | Department of the Air Force | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | TECHNICAL AREA TASKS | $110,219 |
| 2013 | Agricultural Research Service | Contract | TESTING LABORATORIES 541380 | IGF::OT::IGF ACUTE ORAL TOXICITY/PATHOGENICITY TESTING FROM INDEPENDENT LABORATORY. | $71,049 |
| 2013 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | PRECLINICAL TOXICOLOGY AND PHARMACOLOGY OF DRUGS | $0 |
| 2013 | National Institutes of Health | Contract | 541710 | BIOMEDICAL (APPLIED/EXPLORATORY) | -$164,672 |
| 2013 | National Institutes of Health | Contract | 541710 | EVALUATION OF CANDIDATE SMALLPOX VACCINES IN IMMUNE DEFICIENT MOUSE MODELS | -$164,672 |
| 2012 | Department of the Air Force | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | TECHNICAL AREA TASKS | $5,458,114 |
| 2012 | Department of the Air Force | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | TECHNICAL AREA TASKS | $3,535,490 |
| 2012 | Department of the Air Force | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | TECHNICAL AREA TASKS | $3,454,556 |
| 2012 | Department of the Air Force | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | TECHNICAL AREA TASKS | $3,321,972 |
| 2012 | Department of the Air Force | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES 541710 | TECHNICAL AREA TASKS | $2,740,561 |
State business registration
- IIT RESEARCH INSTITUTE IL, Employee benefit plan sponsor (Form 5500), Filed for plan year 2025
- IIT RESEARCH INSTITUTE INCORPORATED FL, Foreign nonprofit corporation (FORNP), Inactive, formed 1992-01-27
- IIT RESEARCH INSTITUTE (CORPORATION) FL, Foreign nonprofit corporation (FORNP), Inactive, formed 1980-01-09
The same business name in the same state, from the state’s official registry data.
Patents
2 US patents filed in the last 20 years.
- IIT Research Institute 2 patents, 2025-04-22 to 2025-04-22 EXACT high confidence: identical full name and state
| Patent | Title | Granted | Source |
|---|---|---|---|
| US 12281060 | Remodilins for airway remodeling and organ fibrosis | 2025-04-22 | PVGPATDIS, file of 2026-04-10 |
| US 12280038 | L-pag derivatives for treatment of sleep disordered breathing (SDB) | 2025-04-22 | PVGPATDIS, file of 2026-04-10 |
The newest patents of the PatentsView assignees above, matched to this record by name (and state).
Trademarks
1 US trademark, 1 live.
- IIT Research Institute 1 marks, IL EXACT high confidence: identical full name and state
| Mark | Serial | Filed | Status | Source |
|---|---|---|---|---|
| IITRI | 77411131 | 2008-03-03 | Registered and renewed | TRCFECO2, file of 2024-03-27 |
The newest marks of the trademark owners above, matched to this record by name (and state).
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | IIT Research Institute | IL | State business registries | name and state |
| Business registration | IIT RESEARCH INSTITUTE | IL | State business registries | name and state |
| Business registration | IIT RESEARCH INSTITUTE (CORPORATION) | IL | State business registries | name and state |
| Business registration | IIT RESEARCH INSTITUTE INCORPORATED | IL | State business registries | name and state |
| Contractor | IIT RESEARCH INSTITUTE | IL | Nonprofit contractors (Form 990) | name and state |
| Plan sponsor | IIT RESEARCH INSTITUTE | IL | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Federal award recipient | IIT RESEARCH INSTITUTE | IL | Federal spending (USAspending) | name and state |
| Patent assignee | IIT Research Institute | IL | Patents (USPTO) | name and state |
| Trademark owner | IIT Research Institute | IL | Trademarks (USPTO) | name and state |
| Wikipedia article | IIT Research Institute | Wikipedia (English) | FUZZY: the same website address and the same name |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
NTEE code General Science, IL first:
- ILLINOIS SCIENCE COUNCIL IL
- CHARIN RESEARCH FOUNDATION INC IL
- SOCIETY OF PLASTICS ENGINEERS IL
- INSTITUTE FOR PUBLIC HEALTH AND WATER RESEARCH IL
- METALCASTING RESEARCH FOUNDATION NFP IL
- LABORATORY FOR ENTHUSIASTIC COLLABORATION NFP IL
- VECTOR SOCIETY NFP IL
- INSTITUTE FOR PHYSICS IL
- PROJECT META IL
- INTERNATIONAL DIGITAL LIFE FOUNDATION IL
In other datasets, the same topic (Science) in IL:
- IPO registrant: BRAUN CONSULTING INC (IPO registrations (S-1, F-1))
- Lobbying client: ABBOTT LABORATORIES (Federal lobbying (LDA))
Interests: General Science · science:research_education · Science
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Census Tract 8411, Cook County, Illinois, place (city or town) Chicago, IL, county Cook County, IL, state Illinois; placed by its ZIP code (county and tract) and city name (place). The tract is the tract holding most of the record's ZIP code (FURP does not geocode street addresses).
- David McCormick was paid $581,526, 7.5 times the median household income in Chicago, IL ($77,902), where 16.8% of residents live in poverty.
- Revenue of $17,520,000 is $6 per resident of Chicago, IL (population 2,711,226).
- That revenue equals 0.02% of all household income in Chicago, IL (1,160,205 households at the median $77,902, about $90,382,289,910).
- 128 employees is 0.0 per 1,000 residents of Chicago, IL.
| Measure | Census tract Census Tract 8411, Cook County, Illinois | Place (city or town) Chicago, IL | County Cook County, IL | State Illinois |
|---|---|---|---|---|
| Population B01003 | 7,324 | 2,711,226 | 5,182,090 | 12,694,798 |
| Population, 2020 census P1 | 7,356 | 2,746,388 | 5,275,541 | 12,812,508 |
| Median age B01002 | 48.7 | 35.8 | 38.0 | 39.0 |
| Under 18 B01001 | 13.7% | 19.4% | 21.1% | 21.8% |
| 65 and over B01001 | 19.7% | 13.8% | 16.0% | 17.0% |
| Households B11001 | 2,875 | 1,160,205 | 2,100,230 | 5,036,449 |
| Foreign born B05002 | 60.1% | 20.9% | 21.7% | 14.7% |
| Median household income B19013 | $44,083 | $77,902 | $83,498 | $83,390 |
| Median family income B19113 | $66,912 | $95,774 | $104,836 | $106,018 |
| Per capita income B19301 | $29,216 | $50,086 | $49,329 | $46,406 |
| Poverty rate B17001 | 20.1% | 16.8% | 13.5% | 11.8% |
| Unemployment rate B23025 | 10.2% | 8.0% | 7.0% | 5.8% |
| Civilian labor force B23025 | 4,118 | 1,517,330 | 2,792,888 | 6,652,134 |
| Mean commute (minutes) B08013 | 26.5 | 33.1 | 31.5 | 27.8 |
| Bachelor's degree or higher B15003 | 25.6% | 44.3% | 42.7% | 37.8% |
| Housing units B25001 | 3,025 | 1,277,054 | 2,276,493 | 5,457,452 |
| Owner-occupied B25003 | 41.2% | 46.0% | 57.7% | 67.1% |
| Renters B25003 | 58.8% | 54.0% | 42.3% | 32.9% |
| Median home value B25077 | $354,600 | $334,100 | $324,500 | $263,300 |
| Median gross rent B25064 | $1,286 | $1,440 | $1,435 | $1,274 |
| White, not Hispanic B03002 | 5.7% | 32.1% | 40.1% | 58.1% |
| Black B03002 | 3.7% | 27.4% | 21.8% | 13.3% |
| Hispanic or Latino B03002 | 2.6% | 29.7% | 26.8% | 18.8% |
| Asian B03002 | 85.3% | 7.2% | 7.9% | 5.9% |
| American Indian and Alaska Native B03002 | 0.9% | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Census Tract 8411, Cook County, Illinois.
Comments